Elevated baseline plasma phospholipid protein (PLTP) levels are an independent predictor of long-term all-cause mortality in patients with diabetes mellitus and known or suspected coronary artery disease

Atherosclerosis

Volumn 239, Issue 2, 2015, Pages 503-508

  Cavusoglu, Erdal ^a,b   Marmur, Jonathan D ^b   Chhabra, Sandeep ^b   Hojjati, Mohammad R ^b   Yanamadala, Sunitha ^b   Chopra, Vineet ^a   Eng, Calvin ^a   Jiang, Xian Cheng ^c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b Downstate Health Sciences University   (United States)

^c SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

Acute coronary syndrome; Atherosclerosis; Biomarkers; Diabetes mellitus; Mortality; Myocardial infarction; Phospholipid transfer protein; PLTP; Prognosis

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CHOLESTEROL; CYSTATIN C; FIBRINOGEN; GROWTH DIFFERENTIATION FACTOR 15; HEMOGLOBIN A1C; INSULIN; LIPOPROTEIN; METFORMIN; MYELOPEROXIDASE; ORAL ANTIDIABETIC AGENT; PHOSPHOLIPID; TROPONIN I; BIOLOGICAL MARKER; PHOSPHOLIPID TRANSFER PROTEIN; PLTP PROTEIN, HUMAN;

AGE; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONGESTIVE HEART FAILURE; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DIABETIC PATIENT; FIBRINOGEN BLOOD LEVEL; FOLLOW UP; HEART INFARCTION; HEMOGLOBIN BLOOD LEVEL; HUMAN; KIDNEY FUNCTION; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MORTALITY; PATHOGENESIS; PATIENT HISTORY OF CORONARY ARTERY BYPASS GRAFT; PHOSPHOLIPID BLOOD LEVEL; PRIORITY JOURNAL; PROSPECTIVE STUDY; BLOOD; CHI SQUARE DISTRIBUTION; KAPLAN MEIER METHOD; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RADIOGRAPHY; RISK FACTOR; TIME; UPREGULATION;

AGED; BIOMARKERS; CHI-SQUARE DISTRIBUTION; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PHOSPHOLIPID TRANSFER PROTEINS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; UP-REGULATION;

EID: 84923081300     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2015.02.017     Document Type: Article

References (32)

1. Jiang X.C., Jin W., Hussain M.M. The impact of phospholipid transfer protein (PLTP) on lipoprotein metabolism. Nutr. Metab. Lond. 2012, 9:75.
2. Bruce C., Beamer L.J., Tall A.R. The implications of the structure of the bactericidal/permeability-increasing protein on the lipid-transfer function of the cholesteryl ester transfer protein. Curr. Opin. Struct. Biol. 1998, 8:426-434.
3. Day J.R., Albers J.J., Lofton-Day C.E., et al. Complete cDNA encoding human phospholipid transfer protein from human endothelial cells. J.Biol. Chem. 1994, 269:9388-9391.
4. Massey J.B., Hickson D., She H.S., et al. Measurement and prediction of the rates of spontaneous transfer of phospholipids between plasma lipoproteins. Biochim. Biophys. Acta 1984, 794:274-280.
5. Lie J., de Crom R., van Gent T., et al. Elevation of plasma phospholipid transfer protein increases the risk of atherosclerosis despite lower apolipoprotein B-containing lipoproteins. J.Lipid Res. 2004, 45:805-811.
6. Jiang X.C., Qin S., Qiao C., et al. Apolipoprotein B secretion and atherosclerosis are decreased in mice with phospholipid-transfer protein deficiency. Nat. Med. 2001, 7:847-852.
7. van Haperen R., van Tol A., van Gent T., et al. Increased risk of atherosclerosis by elevated plasma levels of phospholipid transfer protein. J.Biol. Chem. 2002, 277:48938-48943.
8. Schlitt A., Bickel C., Thumma P., et al. High plasma phospholipid transfer protein levels as a risk factor for coronary artery disease. Arterioscler. Thromb. Vasc. Biol. 2003, 23:1857-1862.
9. Schlitt A., Blankenberg S., Bickel C., et al. PLTP activity is a risk factor for subsequent cardiovascular events in CAD patients under statin therapy: the AtheroGene study. J.Lipid Res. 2009, 50:723-729.
10. Vergeer M., Boekholdt S.M., Sandhu M.S., et al. Genetic variation at the phospholipid transfer protein locus affects its activity and high-density lipoprotein size and is a novel marker of cardiovascular disease susceptibility. Circulation 2010, 122:470-477.
11. Robins S.J., Lyass A., Brocia R.W., et al. Plasma lipid transfer proteins and cardiovascular disease. The Framingham Heart Study. Atherosclerosis 2013, 228:230-236.
12. Cavusoglu E., Marmur J.D., Chhabra S., et al. Relation of baseline plasma phospholipid transfer protein (PLTP) activity to left ventricular systolic dysfunction in patients referred for coronary angiography. Atherosclerosis 2009, 207:261-265.
13. Colhoun H.M., Scheek L.M., Rubens M.B., et al. Lipid transfer protein activities in type 1 diabetic patients without renal failure and nondiabetic control subjects and their association with coronary artery calcification. Diabetes 2001, 50:652-659.
14. Tan K.C., Shiu S.W., Wong Y., et al. Plasma phospholipid transfer protein activity and subclinical inflammation in type 2 diabetes mellitus. Atherosclerosis 2005, 178:365-370.
15. Schneider M., Vergès B., Klein A., et al. Alterations in plasma vitamin E distribution in type 2 diabetic patients with elevated plasma phospholipid transfer protein activity. Diabetes 2004, 53:2633-2639.
16. Emerging Risk Factors Collaboration Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 2010, 375:2215-2222.
17. Fang Z.Y., Prins J.B., Marwick T.H. Diabetic cardiomyopathy: evidence, mechanisms, and therapeutic implications. Endocr. Rev. 2004, 25:543-567.
18. Tzotzas T., Desrumaux C., Lagrost L. Plasma phospholipid transfer protein (PLTP): review of an emerging cardiometabolic risk factor. Obes. Rev. 2009, 10:403-411.
19. Dullaart R.P., Sluiter W.J., Dikkeschei L.D., et al. Effect of adiposity on plasma lipid transfer protein activities: a possible link between insulin resistance and high density lipoprotein metabolism. Eur. J. Clin. Invest 1994, 24:188-194.
20. Riemens S.C., van Tol A., Sluiter W.J., et al. Plasma phospholipid transfer protein activity is related to insulin resistance: impaired acute lowering by insulin in obese type II diabetic patients. Diabetologia 1998, 41:929-934.
21. de Vries R., Dallinga-Thie G.M., Smit A.J., et al. Elevated plasma phospholipid transfer protein activity is a determinant of carotid intima-media thickness in type 2 diabetes mellitus. Diabetologia 2006, 49:398-404.
22. Cavusoglu E., Ruwende C., Chopra V., et al. Relation of baseline plasma ADMA levels to cardiovascular morbidity and mortality at two years in men with diabetes mellitus referred for coronary angiography. Atherosclerosis 2010, 210:226-231.
23. Tall A.R., Krumholz S., Olivecrona T., et al. Plasma phospholipid transfer protein enhances transfer and exchange of phospholipids between very low density lipoproteins and high density lipoproteins during lipolysis. J.Lipid Res. 1985, 26:842-851.
24. Jauhiainen M., Metso J., Pahlman R., et al. Human plasma phospholipid transfer protein causes high density lipoprotein conversion. J.Biol. Chem. 1993, 268:4032-4036.
25. Jiang X.C., Tall A.R., Qin S., et al. Phospholipid transfer protein deficiency protects circulating lipoproteins from oxidation due to the enhanced accumulation of vitamin E. J.Biol. Chem. 2002, 277:31850-31856.
26. Yang X.P., Yan D., Qiao C., et al. Increased atherosclerotic lesions in apoE mice with plasma phospholipid transfer protein overexpression. Arterioscler. Thromb. Vasc. Biol. 2003, 23:1601-1607.
27. Colhoun H.M., Taskinen M.R., Otvos J.D., et al. Relationship of phospholipid transfer protein activity to HDL and apolipoprotein B-containing lipoproteins in subjects with and without type 1 diabetes. Diabetes 2002, 51:3300-3305.
28. Tan K.C., Shiu S.W., Wong Y. Plasma phospholipid transfer protein activity and small, dense LDL in type 2 diabetes mellitus. Eur. J. Clin. Invest 2003, 33:301-306.
29. de Vries R., Groen A.K., Perton F.G., et al. Increased cholesterol efflux from cultured fibroblasts to plasma from hypertriglyceridemic type 2 diabetic patients: roles of pre beta-HDL, phospholipid transfer protein and cholesterol esterification. Atherosclerosis 2008, 196:733-741.
30. Tan K.C., Shiu S.W., Wong Y., et al. Plasma apolipoprotein E concentration is an important determinant of phospholipid transfer protein activity in type 2 diabetes mellitus. Diabetes Metab. Res. Rev. 2006, 22:307-312.
31. Dullaart R.P., Vergeer M., de Vries R., et al. Type 2 diabetes mellitus interacts with obesity and common variations in PLTP to affect plasma phospholipid transfer protein activity. J.Intern. Med. 2012, 271:490-498.
32. Schlitt A., Heine G.H., Jiang X.C., et al. Phospholipid transfer protein in hemodialysis patients. Am. J. Nephrol. 2007, 27(2):138-143.